search

Active clinical trials for "Endometrial Neoplasms"

Results 391-400 of 990

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)...

Lung CancerSolid Tumor9 more

The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).

Terminated14 enrollment criteria

Risk Factors for Endometrial Cancer in Black Women

Endometrial Cancer

RATIONALE: Learning about the risk factors for endometrial cancer in black women may help the study of endometrial cancer in the future. PURPOSE: This clinical trial is studying risk factors for endometrial cancer in black women.

Active13 enrollment criteria

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III,...

Endometrial Cancer

RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving doxorubicin hydrochloride liposome together with carboplatin works in treating patients with recurrent, stage III, or stage IV primary endometrial cancer.

Terminated30 enrollment criteria

Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage...

Endometrial Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen and megestrol may fight endometrial cancer by blocking the absorption of estrogen. It is not yet known whether chemotherapy is more effective than hormone therapy in treating endometrial cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with that of hormone therapy in treating patients who have recurrent, stage III, or stage IV endometrial cancer.

Terminated54 enrollment criteria

A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer...

Prostate CancerSalivary Gland Cancer4 more

The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer

Terminated18 enrollment criteria

NR in Chemo-induced Peripheral Neuropathy

Chemotherapy-induced Peripheral NeuropathyBreast Cancer Metastatic3 more

The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or metastatic head and neck cancer.

Terminated38 enrollment criteria

Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer...

Cancer SurvivorEndometrial Carcinoma5 more

This randomized phase II trial studies how well a health and recovery program works in increasing physical activity level in stage IA-IIIA endometrial cancer survivors. Health and recovery program which includes exercise counseling, Fitbit tracker, and phone or email/text communication may increase the level of physical activity in endometrial cancer survivors and promote and maintain behavior change at a lower cost.

Active12 enrollment criteria

The French E3N Prospective Cohort Study

Breast CancerColo-rectal Cancer12 more

The French E3N cohort was initiated in 1990 to investigate the risk factors associated with cancer and other major non-communicable diseases in women. The participants were insured through a national health system that primarily covered teachers, and were enrolled from 1990 after returning baseline self-administered questionnaires and providing informed consent. The cohort comprised nearly 100 000 women with baseline ages ranging from 40 to 65 years. Follow-up questionnaires were sent approximately every 2-3 years after the baseline and addressed general and lifestyle characteristics together with medical events (cancer, cardiovascular diseases, diabetes, depression, fractures and asthma, among others). The follow-up questionnaire response rate remained stable at approximately 80%. A biological material bank was generated and included blood samples collected from 25 000 women and saliva samples from an additional 47 000 women. Ageing among the E3N cohort provided the opportunity to investigate factors related to agerelated diseases and conditions as well as disease survival.

Active4 enrollment criteria

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Endometrial Cancer

This is an open-label, multi-center, single-arm, two-period Phase 2 study. The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with recurrent or persistent endometrial cancer, who have failed progestin monotherapy or who have been identified as Progesterone Receptor (PrR) negative. All patients must have endometrial cancer PrR status determined from an archival sample at Screening. The PrR status (positive or negative) will be determined by central laboratory by ImmunoHistoChemistry (IHC) testing. There are two treatment periods and a follow-up period within the study.

Terminated31 enrollment criteria

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who...

Gastric CancerTriple Negative Breast Cancer2 more

This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or Metastatic Solid Tumor Who Failed Prior Treatment. This study consists of dose escalation part and dose expansion part.'3+3'design will be adopted in the dose escalation part in subjects with advanced or metastatic gastric cancer who failed prior treatment. The dose of niraparib will be fixed and determined based on baseline weight and platelet count of subjects. Dose expansion part will be expanded at the specified dose level to further assess the safety and preliminary antitumor activity.

Terminated52 enrollment criteria
1...394041...99

Need Help? Contact our team!


We'll reach out to this number within 24 hrs